| Schedule (route) | Endpoint | Vehicle | Dose | Treated/Control (%) | Observations |
|---|---|---|---|---|---|
| Q01DX005 (ip) | median survival time | saline with Tween-80 | 50.0 mg/kg/injection | 110.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline with Tween-80 | 100.0 mg/kg/injection | 104.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline with Tween-80 | 200.0 mg/kg/injection | 97.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline with Tween-80 | 400.0 mg/kg/injection | 105.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX005 (ip) | median survival time | saline with Tween-80 | 800.0 mg/kg/injection | 97.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline with Tween-80 | 12.5 mg/kg/injection | 101.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline with Tween-80 | 25.0 mg/kg/injection | 101.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline with Tween-80 | 50.0 mg/kg/injection | 100.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline with Tween-80 | 100.0 mg/kg/injection | 101.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline with Tween-80 | 200.0 mg/kg/injection | 100.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline with Tween-80 | 400.0 mg/kg/injection | 100.0 | Antitumor endpoint evaluated on day 30; 10/10 animals surviving on day 5 |